BioGenCell has partnered with the University of California San Francisco (UCSF) as part of the company’s Phase II clinical trials. The partnership will focus on the impact of BioGenCell’s treatment on those with chronic limb-threatening ischaemia (CLTI also known as CLI), a debilitating condition commonly associated with diabetes. This is part of a worldwide multi-site […]
